Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); A United Kingdom children's cancer study group (UKCCSG) study

Richard Grundy, C Hutton, H Middleton, J Imeson, Jeremy Pritchard, A Kelsey, HB Marsden, GM Vujanic, RE Taylor

Research output: Contribution to journalArticle

27 Citations (Scopus)


Background. The aims of UKWT2 included consolidating the results for stage III patients obtained in UKWT1 and improving the outcome for patients with inoperable tumours by giving vincristine, actinomycin-D and doxorubicin in an intensive schedule (Intensive AVA). Procedure. The second UK WT trial (UKWT2) ran between July 1986 and September 1991 accruing 448 patients. One hundred and six patients were diagnosed and treated for stage III disease. Six had clear cell sarcoma of the kidney (CCSK) and seven had rhabdoid tumours of the kidney (RTK) and are analysed separately. Oneother patient was excluded from overall analysis. Ninety-two patients were followed for a median of 115 months. Seventy-five received standard chemotherapy and abdominal radiotherapy (RT) according to protocol. Seventeen had stage III disease at immediate nephrectomy, but RT was omitted by physician choice. Thirty-three patients had inoperable disease at diagnosis and received pre-nephrectomy chemotherapy. Results. Overall survival (OS) at 4 years for stage III favourable histology (FH) patients receiving abdominal RT was 83% (CI: 73-89). For children with stage III disease in whom RT was omitted the OS was 82% (CI: 59-97) and for inoperable disease 94% (CI: 78-98). The overall and event-free survival (EFS) of children with stage III CCSK was 100% and was achieved with the majority of patients not receiving RT (CI: 48-100). Three of seven children with RTK are alive EFS and OS 43% (CI: 10-73). For patients treated by abdominal RT the overall local control rate was 94.4% (CI: 86.4-98.5*%), 96.7% (CI: 88.5-99.6%) for flank RT and 83.3% (51.6-98.0%) for whole abdominal radiotherapy (WRT). Conclusions. The outcome for stage III FH disease was similar to that reported for UKWT1 and NWTS-3. The combination of abdominal RT together with 3-drug chemotherapy achieves a high abdominal tumour control rate. Flank RT is probably sufficient for localised turnout rupture. The high cure rates for children in this trial with 'inoperable disease' suggests that treatment should be modified according to their post-chemotherapy stage in order to avoid over-treatment. The high OS for stage III CCSK on this protocol suggests that treatment duration could he curtailed and the role of RT reviewed, though the numbers are small. The prognosis for older children with RTK seems to be better than for younger children although larger studies are required to confirm this. (C) 2003 Wiley-Liss, Inc.
Original languageEnglish
Pages (from-to)311-319
Number of pages9
JournalPediatric Blood & Cancer
Issue number4
Publication statusPublished - 1 Apr 2004


  • stage III
  • inoperable disease
  • radiotherapy
  • Wilms tumour


Dive into the research topics of 'Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); A United Kingdom children's cancer study group (UKCCSG) study'. Together they form a unique fingerprint.

Cite this